Diabetic microangiopathy in KK mice. II. Suppression of Glomerulosclerosis by pyridinolcarbamate.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002219:Carbamates / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D005947:Glucose / Q000378:metabolism; D005964:Glucosyltransferases / Q000378:metabolism; D007668:Kidney / Q000201:enzymology; D007672:Kidney Cortex / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D009929:Organ Size / Q000187:drug effects; D014176:Protein Biosynthesis; D011727:Pyridinolcarbamate / Q000627:therapeutic use*; D013997:Time Factors
D002219:Carbamates; D011727:Pyridinolcarbamate; D005964:Glucosyltransferases; D005947:Glucose